The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer

Biochemical and Biophysical Research Communications

Volumn 396, Issue 1, 2010, Pages 85-89

  Farnebo, Marianne ^a   Bykov, Vladimir J N ^a   Wiman, Klas G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antisense RNA; Apoptosis; APR 246; Cancer therapy; p53; PRIMA 1; Tumor suppressor; Wrap53

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANTINEOPLASTIC AGENT; APR 246; CASPASE 2; DNA; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMATINIB; KRUPPEL LIKE FACTOR 4; LEPTOMYCIN B; MESSENGER RNA; METHYLENEQUINUCLIDINONE; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PRIMA 1; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PUMA PROTEIN; TRANSCRIPTION FACTOR SOX2; TUBERIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CLINICAL TRIAL; DNA DAMAGE; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; SENESCENCE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952305665     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.152     Document Type: Article

References (53)

1. Soussi T., and Wiman K.G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12 (2007) 303-312
2. Vousden K.H., and Prives C. Blinded by the light: the growing complexity of p53. Cell 137 (2009) 413-431
3. Green D.R., and Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 458 (2009) 1127-1130
4. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
5. Bourdon J.C. p53 and its isoforms in cancer. Br. J. Cancer 97 (2007) 277-282
6. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
7. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio Jr. R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., and Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
8. Sherr C.J., and Weber J.D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10 (2000) 94-99
9. In: Hainaut P., and Wiman K.G. (Eds). 25 Years of p53 Research (2005), Springer
10. Brosh R., and Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9 (2009) 701-713
11. Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V.G., Rotter V., Blandino G., and Oren M. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 67 (2007) 2396-2401
12. Muller P.A., Caswell P.T., Doyle B., Iwanicki M.P., Tan E.H., Karim S., Lukashchuk N., Gillespie D.A., Ludwig R.L., Gosselin P., Cromer A., Brugge J.S., Sansom O.J., Norman J.C., and Vousden K.H. Mutant p53 drives invasion by promoting integrin recycling. Cell 139 (2009) 1327-1341
13. Vousden K.H., and Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 9 (2009) 691-700
14. Crighton D., Wilkinson S., O'Prey J., Syed N., Smith P., Harrison P.R., Gasco M., Garrone O., Crook T., and Ryan K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126 (2006) 121-134
15. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., and Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 (2006) 107-120
16. Bykov V.J., Lambert J.M., Hainaut P., and Wiman K.G. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 8 (2009) 2509-2517
17. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., Hee Park S., Thompson T., Karsenty G., Bradley A., and Donehower L.A. p53 mutant mice that display early ageing-associated phenotypes. Nature 415 (2002) 45-53
18. Arum O., and Johnson T.E. Reduced expression of the Caenorhabditis elegans p53 ortholog cep-1 results in increased longevity. J. Gerontol. A Biol. Sci. Med. Sci. 62 (2007) 951-959
19. Bauer J.H., Poon P.C., Glatt-Deeley H., Abrams J.M., and Helfand S.L. Neuronal expression of p53 dominant-negative proteins in adult Drosophila melanogaster extends life span. Curr. Biol. 15 (2005) 2063-2068
20. Matheu A., Maraver A., Klatt P., Flores I., Garcia-Cao I., Borras C., Flores J.M., Vina J., Blasco M.A., and Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448 (2007) 375-379
21. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., and Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11 (2005) 1306-1313
22. Krizhanovsky V., and Lowe S.W. Stem cells: the promises and perils of p53. Nature 460 (2009) 1085-1086
23. Zhang J., and Chen X. Posttranscriptional regulation of p53 and its targets by RNA-binding proteins. Curr. Mol. Med. 8 (2008) 845-849
24. Vilborg A., Glahder J.A., Wilhelm M.T., Bersani C., Corcoran M., Mahmoudi S., Rosenstierne M., Grander D., Farnebo M., Norrild B., and Wiman K.G. The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proc. Natl. Acad. Sci. USA 106 (2009) 15756-15761
25. Le M.T., Teh C., Shyh-Chang N., Xie H., Zhou B., Korzh V., Lodish H.F., and Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 23 (2009) 862-876
26. Zhang Y., Gao J.S., Tang X., Tucker L.D., Quesenberry P., Rigoutsos I., and Ramratnam B. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett. 583 (2009) 3725-3730
27. Mahmoudi S., Henriksson S., Corcoran M., Mendez-Vidal C., Wiman K.G., and Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol. Cell 33 (2009) 462-471
28. Farnebo M. Wrap53, a novel regulator of p53. Cell Cycle 8 (2009) 2343-2346
29. Kim H., You S., Foster L.K., Farris J., and Foster D.N. The rapid destabilization of p53 mRNA in immortal chicken embryo fibroblast cells. Oncogene 20 (2001) 5118-5123
30. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13 (2006) 921-926
31. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
32. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
33. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
34. Foster B.A., Coffey H.A., Morin M.J., and Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286 (1999) 2507-2510
35. Rippin T.M., Bykov V.J., Freund S.M., Selivanova G., Wiman K.G., and Fersht A.R. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21 (2002) 2119-2129
36. Rao C.V., Swamy M.V., Patlolla J.M., and Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res. 68 (2008) 7670-7675
37. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., and Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. USA 105 (2008) 10360-10365
38. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., and Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8 (2002) 282-288
39. Bykov V.J., Zache N., Stridh H., Westman J., Bergman J., Selivanova G., and Wiman K.G. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24 (2005) 3484-3491
40. Bykov V.J., Issaeva N., Selivanova G., and Wiman K.G. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23 (2002) 2011-2018
41. Liang Y., Besch-Williford C., and Hyder S.M. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int. J. Oncol. 35 (2009) 1015-1023
42. Liang Y., Besch-Williford C., Brekken R.A., and Hyder S.M. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res. 67 (2007) 9929-9936
43. Shi H., Lambert J.M., Hautefeuille A., Bykov V.J., Wiman K.G., Hainaut P., and de Fromentel C.C. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis 29 (2008) 1428-1434
44. Zache N., Lambert J.M., Wiman K.G., and Bykov V.J. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell. Oncol. 30 (2008) 411-418
45. Lambert J.M., Gorzov P., Veprintsev D.B., Soderqvist M., Segerback D., Bergman J., Fersht A.R., Hainaut P., Wiman K.G., and Bykov V.J. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15 (2009) 376-388
46. Lambert J.M., Moshfegh A., Hainaut P., Wiman K.G., and Bykov V.J. Mutant p53 reactivation by PRIMA-1(MET) induces multiple signaling pathways converging on apoptosis. Oncogene 29 (2010) 1329-1338
47. Shen J., Vakifahmetoglu H., Stridh H., Zhivotovsky B., and Wiman K.G. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene 27 (2008) 6571-6580
48. Duan W., Gao L., Wu X., Wang L., Nana-Sinkam S.P., Otterson G.A., and Villalona-Calero M.A. MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. Int. J. Cancer (2010) [Epub ahead of print]
49. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., and Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26 (2007) 731-743
50. Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E.P., Wolff B., Yoshida M., and Horinouchi S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 96 (1999) 9112-9117
51. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., and Haber D.A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102 (2005) 7665-7670
52. Nahi H., Merup M., Lehmann S., Bengtzen S., Mollgard L., Selivanova G., Wiman K.G., and Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br. J. Haematol. 132 (2006) 230-236
53. Nahi H., Lehmann S., Mollgard L., Bengtzen S., Selivanova G., Wiman K.G., Paul C., and Merup M. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br. J. Haematol. 127 (2004) 285-291